Sign inSubscribe

target directory

aga2115 clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT07557446
Source recordAI-normalized

A Phase 2 Multi-center, Randomized, Open-Label, Dose Regimen-Finding Study of AGA2115 in Chinese Adults and Adolescents With Type I, III, or IV Osteogenesis Imperfecta

This study is to evaluate the safety and efficacy of AGA2115 at three different dose regimens in Chinese adults and adolescents with Type I, III, or IV Osteogenesis imperfecta (OI).

AI analysis

Indication: Osteogenesis Imperfecta (OI)

Modality: small molecule

Target: AGA2115

Sponsor: Angitia Biopharmaceuticals Guangzhou Limited

Source URL: ClinicalTrials.gov

Source updated: Apr 29, 2026

Ingested: Jun 11, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: AGA2115

View original source fields

Condition raw: Osteogenesis Imperfecta (OI)

Condition normalized: Osteogenesis Imperfecta (OI)

Modality raw: small molecule

Modality normalized: small molecule

Target raw: AGA2115

Target normalized: AGA2115

Open report